No abstract available
Keywords:
ACE inhibitors; COVID-19; Drug treatment; Inflammation; SARS-CoV-2.
MeSH terms
-
Adenosine Monophosphate / analogs & derivatives
-
Adenosine Monophosphate / therapeutic use
-
Alanine / analogs & derivatives
-
Alanine / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antiviral Agents / therapeutic use*
-
Betacoronavirus / pathogenicity*
-
COVID-19
-
Coronavirus Infections / complications
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / virology
-
Dexamethasone / therapeutic use
-
Diabetes Mellitus / diagnosis
-
Diabetes Mellitus / drug therapy*
-
Diabetes Mellitus / virology
-
Drug Repositioning
-
Host-Pathogen Interactions / drug effects
-
Humans
-
Hydroxychloroquine / therapeutic use
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hyperlipidemias / complications
-
Hyperlipidemias / diagnosis
-
Hyperlipidemias / drug therapy*
-
Hyperlipidemias / virology
-
Hypertension / complications
-
Hypertension / diagnosis
-
Hypertension / drug therapy*
-
Hypertension / virology
-
Hypolipidemic Agents / therapeutic use
-
Obesity / complications
-
Obesity / diagnosis
-
Obesity / drug therapy*
-
Obesity / virology
-
Pandemics
-
Pneumonia, Viral / complications
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / virology
-
SARS-CoV-2
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Antiviral Agents
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents
-
remdesivir
-
Adenosine Monophosphate
-
Hydroxychloroquine
-
Dexamethasone
-
Alanine